Drug Profile
NXT 211
Alternative Names: Anti-ferritin antibody-Y90; NXT211; Radiolabelled anti-isoferritin antibodyLatest Information Update: 29 Jun 2011
Price :
$50
*
At a glance
- Originator NEXTherapeutics
- Class Antibodies; Antibody diagnostics; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Hodgkin's disease
Most Recent Events
- 29 Jun 2011 No development reported - Clinical-Phase-Unknown for Hodgkin's disease in USA (unspecified route)
- 29 Jun 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
- 17 Feb 2004 Preclinical trials in Cancer (diagnosis) in USA (unspecified route)